Journal Article

Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma

Zhong, Deyuan, Lai, Chunyou, Su, Yuhao, Yao, Yutong, Liang, Yuxin, Shi, Ying, Huang, Xiaolun, Shang, Jin, Zhang, Zilong, Yan, Su

2024

Overview

Background For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of antiviral therapy for hepatocellular carcinoma (HCC) remains to be further explored. Methods 196 HBV-related HCC patients who received radical hepatectomy and nucleos(t)ide analogues (NAs) therapy at Sichuan Provincial People’s Hospital were enrolled in this study. HCC recurrence, overall survival (OS), early virological (VR) and biochemical responses (BR) of patients were compared between different NAs therapy and the use of anti-programmed cell death protein 1 (PD-1) therapy. Results NAs therapy at different timing of surgery was a strong independent risk factor for postoperative recurrence and overall mortality of HBV-related HCC patients. Furthermore, in HCC patients who received postoperative anti-PD-1 therapy, patients with HBV DNA < 1000 copy/mL had significantly better recurrence-free survival (RFS) and OS than those with HBV DNA ≥ 1000 copy/mL (HR: 7.783; P = 0.002; HR: 6.699; P < 0.001). However, the differences of RFS and OS rates between entecavir group and tenofovir disoproxil fumarate group were not statistically significant. Similar results were also observed in the rates of early VR, BR and combined VR and BR. Conclusion Timely and reasonable preoperative NAs therapy showed clinical benefit in improving the prognosis of patients with HBV-related HCC, even in the case of normal alanine aminotransferase (ALT) level and negative hepatitis e antigen (HBeAg). Furthermore, a possible synergistic effect between antiviral therapy and anti-PD-1 therapy was founded and need further verification.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Alanine transaminase / Anti-PD-1 therapy / Antiretroviral drugs / Antiviral agents / Antiviral drugs / Apoptosis / Biomedical and Life Sciences / Biomedicine / Cancer Research / Cancer therapies / Care and treatment / Cell death / China / Chronic infection / Committees / Comparative analysis / Consent / Control / Curative resection / Development and progression / Diagnosis / Dosage and administration / FDA approval / HCC / Health aspects / Health Promotion and Disease Prevention / Hepatectomy / Hepatitis B / Hepatitis B e antigen / Hepatitis B virus / Hepatocellular carcinoma / Hepatoma / Identification and classification / Immunotherapy / Infection / Liver cancer / Liver cirrhosis / Magnetic resonance imaging / Medical prognosis / Medicine/Public Health / Metastasis / Mortality / Oncology / Patient outcomes / Patients / PD-1 protein / Performance evaluation / Prognosis / Recurrence / Risk factors / Statistical analysis / Surgery / Surgical Oncology / Survival / Tenofovir